Craven Rolf J
Breast Cancer Res. 2008;10(6):113. doi: 10.1186/bcr2191. Epub 2008 Nov 24.
Estrogen receptor (ER) status is a critical biomarker in breast cancer, in large part because the ER is the target of tamoxifen and similar drugs. In the previous issue of Breast Cancer Research, Neubauer and colleagues used a proteomic approach to identify proteins that are differentially regulated by ER in breast tumors. The authors showed that ER-negative tumors have elevated levels of PGRMC1 (progesterone receptor membrane component-1), a hormone receptor component and binding partner for P450 proteins. In contrast, PGRMC1 was phosphorylated in ER-positive tumors. The staining patterns of ER and PGRMC1 were mutually exclusive in breast tumor sections, and PGRMC1 staining was sharply increased in hypoxic areas of the tumor. The results suggest that PGRMC1 is a candidate biomarker for ER status and hypoxia in breast cancer.
雌激素受体（ER）状态是乳腺癌中的一个关键生物标志物，很大程度上是因为ER是他莫昔芬及类似药物的作用靶点。在上一期的《乳腺癌研究》中，诺伊鲍尔及其同事采用蛋白质组学方法来鉴定在乳腺肿瘤中受ER差异调节的蛋白质。作者表明，ER阴性肿瘤中孕酮受体膜成分-1（PGRMC1）水平升高，PGRMC1是一种激素受体成分，也是细胞色素P450蛋白的结合伴侣。相比之下，PGRMC1在ER阳性肿瘤中发生磷酸化。在乳腺肿瘤切片中，ER和PGRMC1的染色模式相互排斥，且PGRMC1染色在肿瘤的缺氧区域急剧增加。结果表明，PGRMC1是乳腺癌中ER状态和缺氧的候选生物标志物。
